Rosa E Cuenca1, Ron R Allison, Claudio Sibata, Gordon H Downie. 1. Photodynamic Therapy Program, Leo Jenkins Cancer Center, Department of Surgery, The Brody School of Medicine, East Carolina University, Greenville, North Carolina 27858, USA. cuencar@mail.ecu.edu
Abstract
BACKGROUND: Chest wall progression of breast carcinoma affects up to 5% of breast cancer patients and is a major source of their pain. Treatment options are limited or may not be offered to these patients. Low-dose Photofrin-induced photodynamic therapy (PDT) offers an excellent clinical response with minimal morbidity. We report our continued experience with PDT in this setting. METHODS: Fourteen patients with more than 500 truncal metastases were treated with PDT. All received off-label Photofrin (.8 mg/kg) i.v. and light treatment at 630 nm from a diode laser with a microlens at a fluence of 1800 mW and a total light dose of 150 to 200 J/cm2 at 48 hours. One patient required re-treatment because of extensive disease. RESULTS: Follow-up was at least 6 months, and several extended to >24 months. All patients demonstrated tumor necrosis, with 9 of 14 complete responses, including with lesions >2 cm in thickness. Disease progression occurred outside of the treatment field. Several patients had initial regression of untreated lesions. Wound care, especially with disease in the deep tissues, was an issue. CONCLUSIONS: Low-dose Photofrin-induced PDT offers patients with chest wall progression a treatment option with an excellent clinical response. To date, the response is prolonged and offers good local control. Surgical oncologists have an active role in this treatment option.
BACKGROUND: Chest wall progression of breast carcinoma affects up to 5% of breast cancerpatients and is a major source of their pain. Treatment options are limited or may not be offered to these patients. Low-dose Photofrin-induced photodynamic therapy (PDT) offers an excellent clinical response with minimal morbidity. We report our continued experience with PDT in this setting. METHODS: Fourteen patients with more than 500 truncal metastases were treated with PDT. All received off-label Photofrin (.8 mg/kg) i.v. and light treatment at 630 nm from a diode laser with a microlens at a fluence of 1800 mW and a total light dose of 150 to 200 J/cm2 at 48 hours. One patient required re-treatment because of extensive disease. RESULTS: Follow-up was at least 6 months, and several extended to >24 months. All patients demonstrated tumor necrosis, with 9 of 14 complete responses, including with lesions >2 cm in thickness. Disease progression occurred outside of the treatment field. Several patients had initial regression of untreated lesions. Wound care, especially with disease in the deep tissues, was an issue. CONCLUSIONS: Low-dose Photofrin-induced PDT offers patients with chest wall progression a treatment option with an excellent clinical response. To date, the response is prolonged and offers good local control. Surgical oncologists have an active role in this treatment option.
Authors: Duska Separovic; Ameeta Kelekar; Arun K Nayak; Adi L Tarca; Kentaro Hanada; Jason S Pierce; Jacek Bielawski Journal: Arch Biochem Biophys Date: 2009-11-26 Impact factor: 4.013
Authors: Isabelle Ferreira; Juliana Ferreira; José Dirceu Vollet-Filho; Lilian T Moriyama; Vanderlei S Bagnato; Daisy Maria Favero Salvadori; Noeme S Rocha Journal: Lasers Med Sci Date: 2012-05-08 Impact factor: 3.161
Authors: Cátia S M Ferreira; Melissa C Cheung; Sotiris Missailidis; Stuart Bisland; Jean Gariépy Journal: Nucleic Acids Res Date: 2008-12-22 Impact factor: 16.971